155 related articles for article (PubMed ID: 32073902)
1. Alpha-Particle Therapy for Multifocal Osteosarcoma: A Hypothesis.
Baranowska-Kortylewicz J; Sharp JG; McGuire TR; Joshi S; Coulter DW
Cancer Biother Radiopharm; 2020 Aug; 35(6):418-424. PubMed ID: 32073902
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.
Subbiah V; Anderson PM; Kairemo K; Hess K; Huh WW; Ravi V; Daw NC; Somaiah N; Ludwig JA; Benjamin RS; Chawla S; Hong DS; Meric-Bernstam F; Ravizzini G; Kleinerman E; Macapinlac H; Rohren E
Clin Cancer Res; 2019 Jul; 25(13):3802-3810. PubMed ID: 30733229
[TBL] [Abstract][Full Text] [Related]
4. Targeted Alpha Therapy and Nanocarrier Approach.
Silindir-Gunay M; Karpuz M; Ozer AY
Cancer Biother Radiopharm; 2020 Aug; 35(6):446-458. PubMed ID: 32302510
[TBL] [Abstract][Full Text] [Related]
5. Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
[TBL] [Abstract][Full Text] [Related]
7. Targeted Alpha Therapy with Thorium-227.
Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
[TBL] [Abstract][Full Text] [Related]
8. Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues.
Zhu C; Bandekar A; Sempkowski M; Banerjee SR; Pomper MG; Bruchertseifer F; Morgenstern A; Sofou S
Mol Cancer Ther; 2016 Jan; 15(1):106-113. PubMed ID: 26586724
[TBL] [Abstract][Full Text] [Related]
9. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.
Anderson PM; Subbiah V; Rohren E
Adv Exp Med Biol; 2014; 804():291-304. PubMed ID: 24924181
[TBL] [Abstract][Full Text] [Related]
10. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
[TBL] [Abstract][Full Text] [Related]
11. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma.
Wang YH; Han XD; Qiu Y; Xiong J; Yu Y; Wang B; Zhu ZZ; Qian BP; Chen YX; Wang SF; Shi HF; Sun X
J Surg Oncol; 2012 Mar; 105(3):235-43. PubMed ID: 21866554
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
15. A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with α Particle-Emitting Ultrasmall Silica Nanoparticles.
Urbanska AM; Khanin R; Alidori S; Wong S; Mello BP; Almeida BA; Chen F; Ma K; Turker MZ; Korontsvit T; Scheinberg DA; Zanzonico PB; Wiesner U; Bradbury MS; Quinn TP; McDevitt MR
Cancer Biother Radiopharm; 2020 Aug; 35(6):459-473. PubMed ID: 32013538
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of Thorium-227/Radium-223 Gamma-Camera Imaging During Radionuclide Therapy.
Larsson E; Brolin G; Cleton A; Ohlsson T; Lindén O; Hindorf C
Cancer Biother Radiopharm; 2020 Sep; 35(7):540-548. PubMed ID: 32486837
[TBL] [Abstract][Full Text] [Related]
17. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
[TBL] [Abstract][Full Text] [Related]
18. C-erbB-2 expression and prognostic significance in osteosarcoma.
Yalçin B; Gedikoğlu G; Kutluk T; Varan A; Akyüz C; Büyükpamukçu M
Pediatr Blood Cancer; 2008 Aug; 51(2):222-7. PubMed ID: 18421709
[TBL] [Abstract][Full Text] [Related]
19. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
20. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
